

02nd November, 2021

To,

Department of Corporate Services

BSE Limited

P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE – 524500**

To,

Corporate Listing Department

National Stock Exchange of India Ltd

Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Respected Sir/Madam,

Sub: Intimation of Board Meeting for the approval of the Un-audited Financial Result of the Company for the quarter / half year ended September 30, 2021

We wish to inform you that the meeting of the Board of Directors of the Company will be held on Friday, **12th November, 2021** at the Corporate Office of the Company at Mumbai at 03:00 P.M.:

- To Consider and approve the Standalone and Consolidated Un-audited Financial Result of the Company for the quarter / half year ended September 30, 2021.
- Any other matter with the permission of the Chair.

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2nd April, 2019 issued by NSE, the Trading Window has been closed with effect from 1st October, 2021 and shall continue to remain closed till 48 hours after the announcement of the financial results on 12th November, 2021.

During the aforesaid period when the Trading Window is closed, designated persons including Promoters, Directors, connected persons, the insiders and their immediate relatives shall not trade in Company's shares / securities.

The above intimation is given to you pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015.

Thanking You,

Yours faithfully,

For Kilitch Drugs (India) Limited



Mukund Mehta
(Managing Director)
DIN:00147876

